Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Jan-Mar;22(1):39-45.
doi: 10.1007/BF02591091.

Beta-thromboglobulin and fibrinopeptide A in diabetes mellitus as markers of vascular damage

Beta-thromboglobulin and fibrinopeptide A in diabetes mellitus as markers of vascular damage

M C Librenti et al. Acta Diabetol Lat. 1985 Jan-Mar.

Abstract

Beta-thromboglobulin (BTG) and fibrinopeptide A (FpA) were studied in 68 non-insulin dependent diabetic patients (NIDD) aged 32-81 with a mean duration of diabetes of 9 +/- 0.8 SEM years and 44 healthy controls, comparable for age and sex. Diabetic patients were subdivided into subsets according to the presence of microvascular disease, macrovascular disease or the absence of these lesions. Patients with microangiopathy (micro- and/or macrovascular disease) had higher HbA1 (a-c) (p less than 0.01), higher blood pressure (p less than 0.05) than both healthy controls and uncomplicated diabetics. Plasma BTG was higher in diabetic patients than in healthy controls (p less than 0.02), and was higher in complicated than in non-complicated diabetic subjects. Fpa was higher in complicated than in non-complicated diabetes (p less than 0.05). No differences were observed between the two subsets of complicated patients. In conclusion, we have shown that increased plasma- and platelet-BTG levels are present in non-insulin dependent diabetic subjects, with normal renal function and that plasma BTG is higher in patients with than in those without vascular disease. Fibrinopeptide A, a sensitive marker of in vivo fibrin formation, was significantly increased in NIDD with vascular complications.

PubMed Disclaimer

References

    1. Thromb Haemost. 1983 Apr 28;49(2):123-7 - PubMed
    1. Lancet. 1978 Feb 4;1(8058):238-40 - PubMed
    1. Thromb Res. 1983 May 1;30(3):245-55 - PubMed
    1. Lancet. 1977 Jul 2;2(8027):16 - PubMed
    1. J Lipid Res. 1970 Nov;11(6):583-95 - PubMed

Publication types